Fundamental research is progressing, with the aim of elucidating the complete molecular and cellular mechanisms of action of HEPHA-440 and understanding the role of cells expressing the LPS receptor (TLR4) in the response to immunotherapy. These advancements will enable the use of this treatment with an optimized benefit-risk balance and determine precisely which patients and cancer types will benefit from it. All articles published as part of the SyStInn project will be freely accessible through the open archive platform HAL.
List of publications:
The SyStInn project has not yet led to the publication of research articles.
